Pharmaceutical Information |
Drug Name |
Abrocitinib |
Drug ID |
BADD_D02527 |
Description |
Abrocitinib is under investigation in clinical trial NCT03796676 (JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis). |
Indications and Usage |
Not Available |
Marketing Status |
investigational |
ATC Code |
D11AH08 |
DrugBank ID |
DB14973
|
KEGG ID |
D11400
|
MeSH ID |
C000634427
|
PubChem ID |
Not Available
|
TTD Drug ID |
Not Available
|
NDC Product Code |
53869-1335; 0069-0235; 63539-236; 63539-336; 63539-436; 53869-1435; 0069-0335; 0069-0435; 53869-1235 |
UNII |
73SM5SF3OR
|
Synonyms |
abrocitinib | N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-1-propanesulfonamide | N-(cis-3-(Methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)cyclobutyl)-propane-1-sulfonamide | 1-Propanesulfonamide, N-(cis-3-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)cyclobutyl)- | PF-04965842 |
|
Chemical Information |
Molecular Formula |
Not Available |
CAS Registry Number |
1622902-68-4 |
SMILES |
Not Available |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|